This open-label , phase II study randomized patients with HER@-positive stage II or III invasive breast cancer to trastuzumab , lapatinib , or both , @ weeks prior to and during chemotherapy with FEC@ for @ courses ; then paclitaxel @ mg/m@ weekly for @ courses , then surgery .